Grant: Project Grant
University of Calgary
$757,352.00
Targeting a unique glutamine dependence in brain tumour stem cells: A novel therapeutic option for GBM
EF 2016-17
Résumé
GBM is the most common and most aggressive adult brain cancer. It is thought that therapeutic resistance and tumour recurrence may be due, in part, to brain tumour stem cells (BTSCs) within these tumours. We have over 100 BTSC lines and have utilized these lines to study GBM biology and for the development of novel, experimental therapeutics. We have recently found that more stem-like populations in BTSCs have different metabolic requirements favouring glutamine over glucose. We aim to use this glutamine dependence to develop experimental therapeutic strategies targeting BTSCs. Our results also show an inverse correlation between the STAT3 pathway activity in BTSCs and this dependence on glutamine metabolism. We plan to combinatorially target these two pathways to help achieve greater therapeutic efficacy in BTSCs.
Programme
Project Grant
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
357394
Name
Weiss Samuel
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Targeting a unique glutamine dependence in brain tumour stem cells: A novel therapeutic option for GBM
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$757,352
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Brain Tumour Stem Cells; Cancer Stem Cells; Experimental Therapeutics; Glioblastoma; Glutamine Dependence; Glycolysis; Metabolism; Stat3 Signalling
Abstract
GBM is the most common and most aggressive adult brain cancer. It is thought that therapeutic resistance and tumour recurrence may be due, in part, to brain tumour stem cells (BTSCs) within these tumours. We have over 100 BTSC lines and have utilized these lines to study GBM biology and for the development of novel, experimental therapeutics. We have recently found that more stem-like populations in BTSCs have different metabolic requirements favouring glutamine over glucose. We aim to use this glutamine dependence to develop experimental therapeutic strategies targeting BTSCs. Our results also show an inverse correlation between the STAT3 pathway activity in BTSCs and this dependence on glutamine metabolism. We plan to combinatorially target these two pathways to help achieve greater therapeutic efficacy in BTSCs.
Competitiondate
201610
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Weiss, Samuel; Luchman, Hema A
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $757,352~ $0~
